Indivior PLC (LON:INDV)

London flag London · Delayed Price · Currency is GBP · Price in GBX
1,015.00
+26.50 (2.68%)
Jun 6, 2025, 4:35 PM BST
-26.61%
Market Cap 1.27B
Revenue (ttm) 905.57M
Net Income (ttm) -47.99M
Shares Out 124.77M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE 11.04
Dividend n/a
Ex-Dividend Date n/a
Volume 617,534
Average Volume 388,096
Open 980.00
Previous Close 988.50
Day's Range 980.00 - 1,017.00
52-Week Range 548.71 - 1,433.00
Beta 0.25
RSI 73.78
Earnings Date Jul 31, 2025

About Indivior

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]

Sector Healthcare
Founded 2014
Employees 1,051
Stock Exchange London Stock Exchange
Ticker Symbol INDV
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Drugmaker Invidior to abandon London listing amid exodus of companies

Firm behind opioid addiction treatment drugs quits London Stock Exchange after moving primary to US last year Business live – latest updates The drugmaker Indivior has become the latest company to aba...

4 days ago - The Guardian

Drug maker Indivior to abandon London stock market for the US

Indivior’s exit comes after the company moved its primary listing to the US’s Nasdaq index last year.

5 days ago - Evening Standard

Drug maker Indivior joins the flight from London share listings

Pharmaceuticals company said most of its product sales and shareholders are US based

5 days ago - Evening Standard

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Pharma firm Indivior said on Monday it will cancel its secondary listing on the London Stock Exchange, effective July 25, maintaining its primary listing on the Nasdaq to reduce costs and better align...

5 days ago - Reuters

UK Stock Market News: Vodafone, Indivior, ME Group

Vodafone announces completion of Three deal, Indivior to cancel London listing, focus on NY, laundry performance cycles up at ME Group

5 days ago - The Armchair Trader

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

SLOUGH, England and RICHMOND, Va. , June 2, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ("O...

5 days ago - PRNewsWire

Indivior Announces Patrick Barry as Chief Commercial Officer

Seasoned commercial executive with more than 30 years of pharmaceutical experience RICHMOND, Va. , May 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patri...

10 days ago - PRNewsWire

Indivior to Participate in Upcoming Investor Events

RICHMOND, Va. , May 13, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference – New Yor...

24 days ago - PRNewsWire

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

SUBLOCADE use during pregnancy showed no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates RICHMOND, Va., May 1, 2025 /PRNewswire/ -- Indivio...

5 weeks ago - PRNewsWire

Indivior: Trying To Break Addiction

Indivior PLC’s recovery hinges on Sublocade’s momentum and market trends, though risks persist in litigation and earnings. Find out why INDV stock is a hold.

5 weeks ago - Seeking Alpha

Indivior (INDV) Q1 2025 Earnings Call

6 weeks ago - The Motley Fool

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Indivior PLC (NASDAQ:INDV) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ETCompany ParticipantsJason Thompson - Head, IRMark Crossley - CEORyan...

6 weeks ago - Seeking Alpha

Indivior Announces Q1 2025 Financial Results

SLOUGH, United Kingdom and RICHMOND, Va. , April 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025.

6 weeks ago - PRNewsWire

A Look at Indivior's Upcoming Earnings Report

Indivior (NASDAQ: INDV) is set to give its latest quarterly earnings report on Thursday, 2025-04-24. Here's what investors need to know before the announcement. Analysts estimate that Indivior will r...

6 weeks ago - Benzinga

Decoding Indivior PLC (INDV): A Strategic SWOT Insight

Decoding Indivior PLC (INDV): A Strategic SWOT Insight

3 months ago - GuruFocus

Two Seas Capital LP Reduces Stake in Indivior PLC

Two Seas Capital LP Reduces Stake in Indivior PLC

3 months ago - GuruFocus

Indivior Announces Further Changes to Board of Directors

RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director...

3 months ago - PRNewsWire

UK's Indivior appoints Joe Ciaffoni as CEO

British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.

3 months ago - Reuters

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

RICHMOND, Va. , Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer.

3 months ago - PRNewsWire

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va....

3 months ago - PRNewsWire